Bb5a31f81ClaimSK Hynix announced a shareholder return package valued at approximately 100 trillion won, or roughly $75 billionAgreeDisagree
Bb5a31f81ClaimSK Hynix stated that its supply of DRAM and high-bandwidth memory chips was fully committed through 2029AgreeDisagree
Bb5a31f81ClaimCost Plus Drugs utilizes robotics and artificial intelligence to produce medications at its Dallas manufacturing plantAgreeDisagree
Bb5a31f81ClaimSK Hynix third-quarter 2026 revenue quadrupled from the previous year to set a company recordAgreeDisagree
Bb5a31f81ClaimSK Hynix third-quarter 2026 net profit tripled compared to the previous year, reaching roughly $30 billionAgreeDisagree
Bb5a31f81ClaimSK Hynix cancelled the planned initial public offering of its U.S. flash memory subsidiary SolidigmAgreeDisagree
Bb5a31f81ClaimMercedes-Benz instituted a voluntary buyout program for support staff amid rising material costs and slowing demand in ChinaAgreeDisagree
Bb5a31f81ClaimCost Plus Marketplace sells generic sterile injectables at a markup of 10% to 12% above cost to clinics and hospitalsAgreeDisagree
Bb5a31f81ClaimSK Hynix shares increased by more than 10% following the release of the company's third-quarter 2026 earnings reportAgreeDisagree
Bb5a31f81ClaimThe United States government placed orders to purchase modular drug manufacturing pods from Cost Plus DrugsAgreeDisagree
Bb5a31f81ClaimCost Plus Drugs pays affiliated independent pharmacies a $12 fill fee per prescriptionAgreeDisagree
Bb5a31f81ClaimThe modular drug manufacturing pods developed by Cost Plus Drugs cost approximately $20 million eachAgreeDisagree
Bb5a31f81ClaimSK Hynix and Samsung together account for nearly half of South Korea's benchmark Kospi indexAgreeDisagree